Skip to content

US · PRAX · BIOTECHNOLOGY

Praxis Precision Medicines, Inc. (PRAX) intrinsic value and stock valuation

$300.43as of 2026-11-21 · Mkt cap 8.9B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Praxis Precision Medicines, Inc. DCF and intrinsic value

InvestorsCraft values PRAX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PRAX’s statements →

Praxis Precision Medicines, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02110 praxismedicines.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-303.27M
20182025
Free cash flow
-$-249.12M
20182025
Total equity
$878.1M+25% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$8.55M$2.45M$0.00$0.00
Operating income-$-326.2M-$-200.16M-$-126.37M-$-214.99M-$-167.33M
Net income-$-303.27M-$-182.82M-$-123.28M-$-214.03M-$-167.06M
EPSd-$-13.48M-$-10.21M-$-18.71M-$-69.72M-$-59.03M
Operating cash flow-$-249.07M-$-131.76M-$-111.14M-$-185.04M-$-124.55M
Capital expenditure-$-60K$0.00-$-50K-$-440K-$-1.05M
Free cash flow-$-249.12M-$-131.76M-$-111.19M-$-185.49M-$-125.6M
Total assets$937.9M$483.1M$88M$115.1M$292.8M
Total debt$110K$1.37M$2.5M$3.5M$4.31M
Net debt-$-357.22M-$-214M-$-78.81M-$-58.12M-$-134.39M
Total equity$878.1M$445.5M$69.7M$76.1M$250.8M
Cash and short-term investments$599.3M$392.6M$81.3M$100.5M$275.9M
Income statement
20252024202320222021
Revenue$0.00$8.55M$2.45M$0.00$0.00
Cost of revenue$140K$152.4M$86.8M$154.4M$0.00
Gross profit-$-140K-$-143.86M-$-84.32M-$-154.44M$0.00
Research and development expenses$267.1M$152.4M$86.8M$155M$120.3M
Selling, general and administrative expenses$59.1M$56.3M$42.1M$59.6M$47.1M
Other expenses$0.00-$-152.41M-$-86.77M-$-154.04M$0.00
Operating expenses$326.1M$56.3M$42.1M$60.6M$167.3M
Cost and expenses$326.2M$208.7M$128.8M$215M$167.3M
Interest income$22.9M$17.4M$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$140K$360K$430K$420K$180K
Ebitda-$-303.13M-$-182.46M-$-122.84M-$-213.57M-$-166.88M
Operating income-$-326.2M-$-200.16M-$-126.37M-$-214.99M-$-167.33M
Total other income/expenses, net$22.9M$17.4M$3.1M$960K$270K
Income before tax-$-303.27M-$-182.82M-$-123.28M-$-214.03M-$-167.06M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-303.27M-$-182.82M-$-123.28M-$-214.03M-$-167.06M
Weighted average shares outstanding$22.5M$17.9M$6.59M$3.07M$2.83M
Weighted average diluted shares outstanding$22.5M$17.9M$6.59M$3.07M$2.83M
Balance sheet
20252024202320222021
Cash and short-term investments$599.3M$392.6M$81.3M$100.5M$275.9M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$610.9M$404.4M$84.9M$110.8M$287.4M
Property, plant and equipment, net$240K$1.36M$2.65M$3.87M$4.87M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$77M$0.00$0.00$0.00
Total non-current assets$327M$78.7M$3.07M$4.29M$5.34M
Total assets$937.9M$483.1M$88M$115.1M$292.8M
Accounts payable$24.6M$12.5M$5.82M$14.7M$10.8M
Short-term debt$110K$1.26M$1.13M$1M$810K
Deferred revenue$0.00$0.00$1.39M$2.82M$0.00
Total current liabilities$59.8M$37.6M$15.8M$34.3M$38.4M
Long-term debt$0.00$110K$1.37M$2.5M$3.5M
Deferred revenue, non-current$0.00$0.00$1.16M$2.18M$0.00
Total non-current liabilities$0.00$110K$2.53M$4.68M$3.5M
Capital lease obligations$110K$1.37M$2.5M$3.5M$4.31M
Total liabilities$59.8M$37.7M$18.3M$39M$41.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.14B-$-836.74M-$-653.92M-$-530.64M-$-316.62M
Accumulated other comprehensive income (loss)$560K$650K$0.00-$-170K-$-180K
Total equity$878.1M$445.5M$69.7M$76.1M$250.8M
Total investments$242M$254.2M$0.00$38.9M$137.2M
Total debt$110K$1.37M$2.5M$3.5M$4.31M
Net debt-$-357.22M-$-214M-$-78.81M-$-58.12M-$-134.39M
Cash flow statement
20252024202320222021
Net income-$-303.27M-$-182.82M-$-123.28M-$-214.03M-$-167.06M
Depreciation and amortization-$-3.45M$360K$430K$420K$180K
Stock-based compensation$33.9M$41.4M$24.9M$28.6M$22.7M
Change in working capital$22.7M$10.9M-$-13.03M-$-1.78M$16.1M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$12.1M$6.71M-$-8.86M$3.89M$7.27M
Net cash provided by operating activities-$-249.07M-$-131.76M-$-111.14M-$-185.04M-$-124.55M
Investments in property, plant and equipment-$-60K$0.00-$-50K-$-440K-$-1.05M
Acquisitions, net$0.00$0.00$0.00-$-97.33M$139.5M
Net cash used for investing activities-$-311.15M-$-248.49M$39M$96.9M-$-140.52M
Common stock issued$704.3M$512M$91.6M$9.56M$105.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$702.2M$514.3M$91.9M$10.5M$107.6M
Net change in cash$142M$134.1M$19.7M-$-77.69M-$-157.49M
Cash at end of period$357.8M$215.8M$81.7M$62M$139.7M
Operating cash flow-$-249.07M-$-131.76M-$-111.14M-$-185.04M-$-124.55M
Capital expenditure-$-60K$0.00-$-50K-$-440K-$-1.05M
Free cash flow-$-249.12M-$-131.76M-$-111.19M-$-185.49M-$-125.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Praxis Precision Medicines, Inc.

        Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

        CEO
        Marcio Silva De'Souza
        Employees
        168
        Beta
        2.76

        Explore

        Frequently asked questions

        What is the intrinsic value of Praxis Precision Medicines, Inc. (PRAX)?

        InvestorsCraft does not currently publish an intrinsic value for PRAX. How the IC value is calculated.

        Is PRAX undervalued?

        InvestorsCraft does not publish an undervaluation signal for PRAX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.